Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PBF-999 in Healthy Volunteers
NCT02907294Phase 1Terminated
- Sponsor
- Palobiofarma
- Start
- Mar 2016
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PBF-999 in Huntington disease (HD) (3 arms), sponsored by Palobiofarma. Primary endpoint: Number of Participants with Serious and Non-Serious Adverse Events. Started Mar 2016; status: terminated.
02
Drugs
PBF-999
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NCT02907294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02907294.